Erelzi 50 mg solution for injection in Pre Filled pen – patient leaflet, side effects, dosage

1 What Erelzi is and what it is used for

Erelzi is a medicine that is made from two human proteins. It blocks the activity of another protein in the body that causes inflammation. Erelzi works by reducing the inflammation associated with certain diseases.

In adults (aged 18 and over), Erelzi can be used for moderate or severe rheumatoid arthritis,

psoriatic arthritis, severe axial spondyloarthritis including ankylosing spondylitis, and

moderate or severe psoriasis - in each case usually when other widely used treatments have not worked well enough or are not suitable for you.

For rheumatoid arthritis, Erelzi is usually used in combination with methotrexate, although it may also be used alone if treatment with methotrexate is unsuitable for you. Whether used alone or in combination with methotrexate, Erelzi can slow down the damage to your joints caused by the rheumatoid arthritis and improve your ability to do normal daily activities. For psoriatic arthritis patients with multiple joint involvement, Erelzi can improve your ability to do normal daily activities. For patients with multiple symmetrical painful or swollen joints (e.g., hands, wrists and feet), Erelzi can slow down the structural damage to those joints caused by the disease.

Erelzi is also prescribed for the treatment of the following diseases in children and adolescents:

• For the following types of juvenile idiopathic arthritis

  when treatment with methotrexate has not worked well enough or is not suitable for them:

  • Polyarthritis (rheumatoid factor positive or negative)

    and extended oligoarthritis in patients from the age of 2 years and weighing 62.5 kg or more.

  • Psoriatic arthritis in patients from the age of 12 years

    and weighing 62.5 kg or more.

• For enthesitis-related arthritis in patients from the age

  of 12 years and weighing 62.5 kg or more when other widely used treatments have not worked well enough or are not suitable for them.

• Severe psoriasis in patients from the age of 6 years and

  weighing 62.5 kg or more who have had an inadequate response to (or are unable to take) phototherapies or other systemic therapies.

2 What you need to know before you use Erelzi

Do not use Erelzi

• if you, or the child you are caring for, are allergic to

  etanercept or any of the other ingredients of Erelzi (listed in section 6). If you or the child experience allergic reactions such as chest tightness, wheezing, dizziness or rash, do not inject more Erelzi, and contact your doctor immediately.

  • if you or the child have, or are at risk of developing

    a serious blood infection called sepsis. If you are not sure, please contact your doctor.

  • if you or the child have an infection of any kind. If you are

    not sure, please talk to your doctor.

Warnings and precautions

Talk to your doctor before taking Erelzi.

• Allergic reactions: If you or the child experience allergic

  reactions such as chest tightness, wheezing, dizziness or rash, do not inject more Erelzi, and contact your doctor immediately.

• Infections/surgery: If you or the child develop a new

  infection, or are about to have any major surgery, your doctor may wish to monitor the treatment with Erelzi.

• Infections/diabetes: Tell your doctor if you or the child

  have a history of recurrent infections or suffer from diabetes or other conditions that increase the risk of infection.

• Infections/monitoring: Tell your doctor of any recent

  travel outside the European region. If you or the child develop symptoms of an infection such as fever, chills or cough, notify your doctor immediately. Your doctor may decide to continue to monitor you or the child for the presence of infections after you or the child stop using Erelzi.

• Tuberculosis: As cases of tuberculosis have been reported

  in patients treated with Erelzi, your doctor will check for signs and symptoms of tuberculosis before starting Erelzi. This may include a thorough medical history, a chest X-ray and a tuberculin test. The conduct of these tests should be recorded on the Patient Card. It is very important that you tell your doctor if you or the child have ever had tuberculosis, or have been in close contact with someone who has had tuberculosis. If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy, tell your doctor immediately.

• Hepatitis B: Tell your doctor if you or the child have or

  have ever had hepatitis B. Your doctor should test for the presence of hepatitis B infection before you or the child begin treatment with Erelzi. Treatment with Erelzi may result in reactivation of hepatitis B in patients who have previously been infected with the hepatitis B virus. If this occurs, you should stop using Erelzi.

• Hepatitis C: Tell your doctor if you or the child have

  hepatitis C. Your doctor may wish to monitor the treatment with Erelzi in case the infection worsens.

• Blood disorders: Seek medical advice immediately

  if you or the child have any signs or symptoms such as persistent fever, sore throat, bruising, bleeding or paleness. Such symptoms may point to the existence of potentially life-threatening blood disorders, which may require discontinuation of Erelzi.

• Nervous system and eye disorders: Tell your doctor

  if you or the child have multiple sclerosis, optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of the spinal cord). Your doctor will determine if Erelzi is an appropriate treatment.

• Congestive heart failure: Tell your doctor if you or

  the child have a history of congestive heart failure, because Erelzi needs to be used with caution under these circumstances.

• Cancer: Tell your doctor if you have or have ever had

  lymphoma (a type of blood cancer) or any other cancer before you are given Erelzi.

Package leaflet: Information for the user

Erelzi® 50 mg

solution for injection in pre-filled pen

etanercept

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

• Keep this leaflet. You may need to read it again.

• Your doctor will also give you a Patient Card, which contains important safety information that you need to be aware of

  before and during treatment with Erelzi.

• If you have any further questions, ask your doctor, pharmacist or nurse.

• This medicine has been prescribed for you or a child in your care. Do not pass it on to others. It may harm them, even if their

  signs of illness are the same as yours or those of the child you are caring for.

• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See

  section 4.

SZ00000LT000

Erelzi® 50 mg

solution for injection in pre-filled pen etanercept

Erelzi® 50 mg

solution for injection in pre-filled pen

etanercept

PIL.0191.006.0d

Signature Panel:

Signature

Signature Regulatory

Quality

Patients with severe rheumatoid arthritis, who have had the

disease for a long time, may be at higher than average risk of developing lymphoma.

Children and adults taking Erelzi may have an increased

risk of developing lymphoma or another cancer. Some children and teenage patients who have received

Erelzi or other medicines that work the same way as Erelzi have developed cancers, including unusual types, which sometimes resulted in death.

Some patients receiving Erelzi have developed skin cancers.

Tell your doctor if you or the child develop any change in the appearance of the skin or growths on the skin.

• Chickenpox: Tell your doctor if you or the child are

exposed to chickenpox when using Erelzi. Your doctor will determine if preventive treatment for chickenpox is appropriate.

• Alcohol abuse: Erelzi should not be used for the treatment

  of hepatitis related to alcohol abuse. Please tell your doctor if you or the child in your care have a history of alcohol abuse.

• Wegener’s granulomatosis: Erelzi is not recommended

for the treatment of Wegener’s granulomatosis, a rare inflammatory disease. If you or the child in your care have Wegener’s granulomatosis, talk to your doctor.

• Anti-diabetic medicines: Tell your doctor if you or

the child have diabetes or are taking medicines to treat diabetes. Your doctor may decide if you or the child need less anti-diabetic medicine while using Erelzi. Children and adolescents

Erelzi is not indicated for use in children and adolescents who weigh less than 62.5 kg.

• Vaccinations: If possible, children should be up to date

with all vaccinations before using Erelzi. Some vaccines, such as oral polio vaccine, should not be given while using Erelzi. Please consult your doctor before you or the child receive any vaccines.

Erelzi should not normally be used in children with polyarthritis or extended oligoarthritis below the age of 2 years or weighing less than 62.5 kg, or in children with enthesitis-related arthritis or psoriatic arthritis below the age of 12 years or weighing less than 62.5 kg, or in children with psoriasis below the age of 6 years or weighing less than 62.5 kg.

Other medicines and Erelzi

Tell your doctor or pharmacist if you or the child are taking, have recently taken or might take any other medicines (including anakinra, abatacept or sulfasalazine), even those not prescribed by the doctor.

You or the child should not use Erelzi with medicines that contain the active substance anakinra or abatacept. Pregnancy and breast-feeding

Erelzi should only be used during pregnancy if clearly needed. You should consult your doctor if you become pregnant, think you may be pregnant, or are planning to have a baby.

If you received Erelzi during pregnancy, your baby may have a higher risk of getting an infection. In addition, one study found more birth defects when the mother had received etanercept in pregnancy, compared with mothers who had not received etanercept or other similar medicines (TNF antagonists), but there was no particular kind of birth defect reported. Another study found no increased risk of birth defects when the mother had received etanercept in pregnancy. Your doctor will help you to decide whether the benefits of treatment outweigh the potential risk to your baby.

Talk to your doctor if you want to breastfeed while on Erelzi treatment. It is important that you tell your baby’s doctors and other healthcare professionals about the use of Erelzi during pregnancy and breastfeeding before your baby receives any vaccine Driving and using machines

The use of Erelzi is not expected to affect the ability to drive or use machines.

Erelzi contains sodium

This medicinal product contains less than 1 mmol sodium (23 mg) per 50 mg, that is to say essentially ‘sodium-free’.

3 How to use Erelzi

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. If you feel that the effect of Erelzi is too strong or too weak, talk to your doctor or pharmacist.

You have been prescribed a 50 mg strength of Erelzi. A 25 mg strength of Erelzi is available for doses of 25 mg. Use in adult patients (aged 18 years or over)

Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis including ankylosing spondylitis The usual dose is 25 mg given twice a week or 50 mg once a week as an injection under the skin. However, your doctor may determine an alternative frequency at which to inject Erelzi. Plaque psoriasis

The usual dose is 25 mg twice a week or 50 mg once a week. Alternatively, 50 mg may be given twice a week for up to 12 weeks, followed by 25 mg twice a week or 50 mg once a week.

Your doctor will decide how long you should use Erelzi and whether retreatment is needed based on your response. If Erelzi has no effect on your condition after 12 weeks, your doctor may tell you to stop using this medicine.

Use in children and adolescents

The appropriate dose and frequency of dosing for the child or adolescent will depend on body weight and disease. Your doctor will determine the correct dose for the child and will prescribe an appropriate strength of etanercept. Paediatric patients weighing 62.5 kg or more can be dosed 25 mg given twice a week or 50 mg given once a week using a fixed-dose pre-filled syringe or pre-filled pen.

Other etanercept products with appropriate dosage forms for children are available.

For polyarthritis or extended oligoarthritis in patients from the age of 2 years and weighing 62.5 kg or more, or enthesitis-related arthritis or psoriatic arthritis in patients from the age of 12 years and weighing 62.5 kg or more, the usual dose is 25 mg given twice a week or 50 mg given once a week. For psoriasis in patients from the age of 6 years and weighing 62.5 kg or more, the usual dose is 50 mg and should be given once weekly. If Erelzi has no effect on the child’s condition after 12 weeks, your doctor may tell you to stop using this medicine. The doctor will provide you with detailed directions for preparing and measuring the appropriate dose.

Method and route of administration

Erelzi is administered by an injection under the skin (by subcutaneous injection).

Detailed instructions on how to inject Erelzi are provided in section 7, “Instructions for use of the Erelzi SensoReady pen”.

Do not mix the Erelzi solution with any other medicine. To help you remember, it may be helpful to write in a diary which day(s) of the week Erelzi should be used. If you use more Erelzi than you should

If you have used more Erelzi than you should (either by injecting too much on a single occasion or by using it too frequently), talk to a doctor or pharmacist immediately. Always have the outer carton of the medicine with you, even if it is empty.

If you forget to inject Erelzi

If you forget a dose, you should inject it as soon as you remember, unless the next scheduled dose is the next day; in which case you should skip the missed dose. Then continue to inject the medicine on the usual day(s). If you do not remember until the day that the next injection is due, do not take a double dose (two doses on the same day) to make up for a forgotten dose.

If you stop using Erelzi

Your symptoms may return upon discontinuation. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4 Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Allergic reactions

If any of the following happen, do not inject more Erelzi. Tell your doctor immediately, or go to the casualty department at your nearest hospital.

• Trouble swallowing or breathing
• Swelling of the face, throat, hands, or feet

• Feeling nervous or anxious, throbbing sensations, sudden

  reddening of the skin and/or a warm feeling

• Severe rash, itching, or hives (elevated patches of red or

  pale skin that often itch)

Serious allergic reactions are rare. However, any of the above symptoms may indicate an allergic reaction to Erelzi, so you should seek immediate medical attention.

Serious side effects

If you notice any of the following, you or the child may need urgent medical attention.

• Signs of serious infections such as high fever that may

  be accompanied by cough, shortness of breath, chills, weakness, or a hot, red, tender, sore area on the skin or joints;

• Signs of blood disorders, such as bleeding, bruising, or

  paleness;

• Signs of nerve disorders, such as numbness or tingling,

  changes in vision, eye pain, or onset of weakness in an arm or leg;

• Signs of heart failure or worsening heart failure, such

  as fatigue or shortness of breath with activity, swelling in the ankles, a feeling of fullness in the neck or abdomen, night-time shortness of breath or coughing, bluish colour of the nails or the lips;

• Signs of cancers: cancers may affect any part of the body

  including the skin and blood, and possible signs will depend on the type and location of the cancer. These signs may include weight loss, fever, swelling (with or without pain), persistent cough, presence of lumps or growths on the skin;

• Signs of autoimmune reactions (where antibodies are

  made that may harm normal tissues in the body) such as pain, itching, weakness, and abnormal breathing, thinking, sensation, or vision;

• Signs of lupus or lupus-like syndrome, such as weight

  changes, persistent rash, fever, joint or muscle pain, or fatigue;

• Signs of inflammation of the blood vessels such as pain,

  fever, redness or warmth of the skin, or itching. These are rare or uncommon side effects, but are serious conditions (some of which may rarely be fatal). If these signs occur, tell your doctor immediately, or visit the casualty department at your nearest hospital.

The known side effects of Erelzi include the following in groups of decreasing frequency:

• Very common (may affect more than 1 in 10 people): Infections (including colds, sinusitis, bronchitis, urinary

  tract infections and skin infections); injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling) (these do not occur as often after the first month of treatment; some patients have developed a reaction at an injection site that was recently used); and headache.

• Common (may affect up to 1 in 10 people): Allergic reactions; fever; rash; itching; antibodies directed

  against normal tissue (autoantibody formation).

• Uncommon (may affect up to 1 in 100 people): Serious infections (including pneumonia, deep skin

  infections, joint infections, blood infection, and infections at various sites); worsening of congestive heart failure; low red blood cell count, low white blood cell count, low neutrophil (a type of white blood cell) count; low blood platelet count; skin cancer (excluding melanoma); localised swelling of the skin (angioedema); hives (elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or worsening); inflammation of the blood vessels affecting multiple organs; elevated liver blood tests (in patients also receiving methotrexate treatment, the frequency of elevated liver blood tests is common); abdominal cramps and pain, diarrhoea, weight loss or blood in the stool (signs of bowel problems).

• Rare (may affect up to 1 in 1,000 people):

  Serious allergic reactions (including severe localised

  swelling of the skin and wheezing); lymphoma (a type of blood cancer); leukaemia (cancer affecting the blood and bone marrow); melanoma (a type of skin cancer); combined low platelet, red, and white blood cell count; nervous system disorders (with severe muscle weakness and signs and symptoms similar to those of multiple sclerosis or inflammation of the nerves of the eyes or spinal cord); tuberculosis; new onset congestive heart failure; seizures; lupus or lupus-like syndrome (symptoms may include persistent rash, fever, joint pain, and tiredness); skin rash, which may lead to severe blistering and peeling of the skin; lichenoid reactions (itchy reddish-purple skin rash and/or threadlike white-grey lines on mucous membranes);

  inflammation of the liver caused by the body’s own immune system (autoimmune hepatitis; in patients also receiving methotrexate treatment, the frequency is uncommon); immune disorder that can affect the lungs, skin and lymph nodes (sarcoidosis); inflammation or scarring of the lungs (in patients also receiving methotrexate treatment, the frequency of inflammation or scarring of the lungs is uncommon).

  • Very rare (may affect up to 1 in 10,000 people): Failure of the bone marrow to produce crucial blood cells.

  • Not known (frequency cannot be estimated from the

    available data):

    Merkel cell carcinoma (a type of skin cancer); Kaposi’s

    sarcoma (a rare cancer related to infection with human herpes virus 8. Kaposi’s sarcoma most commonly appears as purple lesion on the skin); excessive activation of white blood cells associated with inflammation (macrophage activation syndrome); recurrence of hepatitis B (a liver infection); damage to the tiny filters inside your kidneys leading to poor kidney function (glomerulonephritis), worsening of a condition called dermatomyositis (muscle inflammation and weakness with an accompanying skin rash).

Additional side effects in children and adolescents

The side effects and their frequencies seen in children and adolescents are similar to those described above.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.

Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

5 How to store Erelzi

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and the label of the pre-filled SensoReady pen after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2 °C – 8 °C). Do not freeze. Keep the pre-filled pens in the outer carton in order to protect from light.

After taking a pre-filled pen from the refrigerator, wait approximately 15-30 minutes to allow the Erelzi solution in the pen to reach room temperature. Do not warm in any other way. Immediate use is then recommended. Erelzi may be stored outside of the refrigerator at temperatures up to a maximum of 25 °C for a single period of up to four weeks; after which, it should not be refrigerated again. Erelzi should be discarded if not used within four weeks after removal from the refrigerator. It is recommended that you record the date that Erelzi is removed from the refrigerator and the date after which Erelzi should be discarded (no more than 4 weeks following the removal from the refrigerator).

Inspect the solution in the pen by looking through the clear viewing window. The solution should be clear or slightly opalescent, colourless to slightly yellowish, and may contain small white or almost translucent particles of protein. This appearance is normal for Erelzi. Do not use the solution if it is discoloured, cloudy, or if particles other than those described above are present. If you are concerned with the appearance of the solution, then contact your pharmacist for assistance. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6 Contents of the pack and other information

What Erelzi contains

The active substance is etanercept.

Each pre-filled pen contains 50 mg of etanercept. The other ingredients are citric acid anhydrous, sodium citrate dihydrate, sodium chloride, sucrose, L-lysine hydrochloride, sodium hydroxide, hydrochloric acid and water for injections. What Erelzi looks like and contents of the pack

Erelzi is supplied as a solution for injection in a pre-filled pen (SensoReady). The SensoReady pen contains a clear or slightly opalescent, colourless to slightly yellowish solution for injection (injection). The pre-filled syringes are made of type I glass, a rubber plunger stopper (bromobutyl rubber), a plunger rod, an attached stainless steel 29 gauge needle and needle cap (thermoplastic elastomer).

Each pack contains 1, 2 or 4 pens, multipacks contain 12 (3 packs of 4) pens.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Sandoz GmbH

Biochemiestrasse 10

A 6250 Kundl

Austria

Manufacturer

Sandoz GmbH Schaftenau

Biochemiestrasse 10

A 6336 Langkampfen

Austria

Or

Novartis Pharmaceutical Manufacturing GmbH Biochemiestrasse 10

6336 Langkampfen

Austria

This leaflet was last revised in 06/2024

7 Instructions for use of the Erelzi pre-filled pen

Read ALL the way through these instructions before injecting. The same information is also available on www.erelzi.eu and through the code below.

www.erelzi.eu

These instructions are to help you to inject correctly using the Erelzi pre-filled pen.

It is important not to try to inject yourself until you have been trained by your doctor, nurse or pharmacist.

Your Erelzi pre-filled pen:

Erelzi pre-filled pen

shown with the cap removed. Do not remove the cap until you are ready to inject.

Store your boxed pen in a refrigerator, between 2 °C to 8 °C and out of the sight and reach of children.

• Do not freeze the pen.
• Do not shake the pen.
• Do not use the pen if it has been dropped with the cap removed.

For a more comfortable injection, take the pen out of the refrigerator

15-30 minutes before injecting to allow it to reach room temperature.

What you need for your injection:

Included in the carton:

A new and unused Erelzi pre-filled pen.

Not included in the carton:

• Alcohol wipe
• Cotton ball or gauze
• Sharps disposal container

Before your injection:

1. 1. Important safety checks before you inject:

The solution should be clear or slightly opalescent, colourless to slightly yellowish, and may contain small white or almost translucent particles of protein. This appearance is normal for Erelzi.

Do not use if the liquid is cloudy, discoloured, or has large lumps, flakes, or coloured particles. Do not use the pen if the expiry date has passed.

Do not use if the safety seal has been broken.

Contact your pharmacist if the pen fails any of these checks.

2a. Choose your injection site:

• The recommended site is the front of the thighs. You may also use the lower abdomen, but not the area 5 centimetres around the navel (belly button).
• Choose a different site each time you give yourself an injection.
• Do not inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with scars or stretch marks. If you have psoriasis, you should NOT inject directly into any raised, thick, red, or scaly skin patches or lesions (“psoriasis skin lesions”).

2b. Caregivers and healthcare professionals only:

• If a caregiver or healthcare professional is giving you your injection, they may also inject into your outer upper arm.
• Cleaning your injection site:
• Wash your hands with soap and hot water.
• Using a circular motion, clean the injection site with the alcohol swab. Leave it to dry before injecting.
• Do not touch the cleaned area again before injecting.

Your injection:

1. 4. Removing the cap:
2. • Only remove the cap when you are ready to use the pen.
3. • Twist off the cap in the direction of the arrows.
4. • Throw away the cap. Do not try to re-attach the cap.
5. • Use the pen within 5 minutes of removing the cap.
6. 5. Holding your pen:
7. •

   Hold the pen at 90 degrees to the cleaned injection site.

   Correct Incorrect